Navigation Links
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
Date:10/15/2008

X354, a CCR1 antagonist currently in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional fina
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
3. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
4. New molecular imaging techniques may lead to advances in disease treatment
5. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Human Genome Sciences Advances Oncology Portfolio
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Genetic Engineering & Biotechnology News reports on advances in miRNA
11. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Study reveals how Arctic food webs affect mercury in polar bears 2Why King Kong failed to impress 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 1New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI 28TM 29 for Noninvasive and Continuous Fluid Monitoring 4588 6Xanodyne Announces Appointment of Mr Vaughn M Kailian of MPM Capital to the Board of Directors 48789 1Xanodyne Announces Appointment of Mr Vaughn M Kailian of MPM Capital to the Board of Directors 48789 2Dual role in breast tissue for a protein involved in leukemia 8815 1Dual role in breast tissue for a protein involved in leukemia 8815 2